New pill aims to slow lung scarring in IPF patients
NCT ID NCT07600021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental tablet called SYH2059 in 156 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants will receive either the drug or a placebo to see if it can slow the decline in lung function. The goal is to find a safe and effective treatment to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care